Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prazosin for Prevention of COVID-19 Cytokine Storm
NCT04365257Phase 2Terminated
- Sponsor
- Johns Hopkins University
- Start
- May 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Prazosin with Standard of Care (2 arms). Primary endpoints: Death at 60 days, Hospitalized, Requiring Mechanical Ventilation and/or High Flow Nasal Cannula and/or ICU/CCU Admission and/or ECMO at 60 days and 4 more. Started May 2020; status: terminated.
02
Drugs
prazosin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04365257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365257.